Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA). The announcement was made last evening at the J.P. Morgan Healthcare Conference in San Francisco. Yvonne will be recognized at HBA’s 34th annual Woman of the Year event on May 10 in New York City.

The HBA Woman of the Year award honors an executive leader who has made extraordinary contributions to healthcare and the advancement of women in the workplace.

“During her three decades of leadership in the biopharmaceutical industry, Yvonne has made an enormous impact through her work to enable the development and delivery of medicines that have improved the lives of people around the world,” said Mary Stutts, CEO of HBA. “Yvonne is an inspirational and purpose-driven leader with a passion for advancing health equity globally and a deep commitment to building an inclusive, equitable, and supportive workplace culture where women—and all employees—can thrive personally and professionally.”

Yvonne joined Alnylam in 2016 as Chief Operating Officer, was promoted to President and COO in 2020, and was appointed a Director in late 2021 and Chief Executive Officer in January 2022. Under her leadership, Alnylam has continued to drive the RNAi revolution that is changing medicine, while consistently earning recognition as a socially responsible company and exceptional workplace globally. Alnylam has been named among Fortune’s Best Workplaces for Women, included on the Bloomberg Gender Equality Index, and ranked as a Best Workplace for Parents. Alnylam has also won recognition multiple years in a row as a top employer by Science Magazine and the Boston Globe, been named a Great Place to Work in many regions outside the U.S., and earned inclusion in Newsweek’s list of America’s Most Responsible Companies.

“Yvonne demonstrates leadership from the front,” said David Pyott, retired chairman and CEO of Allergan and a member of Alnylam’s board of directors. “She develops, mentors, and supports colleagues at all levels. She is a kind and caring person who is a great listener. She creates an environment where dedication to the patient is first and foremost. Yvonne is well-recognized by other industry and healthcare leaders for her rare combination of personal charisma, scientific acumen, and business savvy.”